Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE approves raft of drugs

  • Comment
NICE has made a series of recommendations in technology appraisals for new drugs.

NICE has made a series of recommendations in technology appraisals for new drugs.

Rituximab in combination with methotrexate has been recommended as an option for the treatment of refractory rheumatoid arthritis.

But NICE said rituximab and methotrexate should only be used if other disease modifying anti-rheumatic drugs have not worked, and there is an adequate response to it.

Repeat courses should only be given every six months and all courses should be monitored by specialists, the institute ruled.

Adalimumab has also been approved for treatment of moderate to severe psoriatic arthritis and natalizumab has been recommended for treating highly active relapsing-remitting multiple sclerosis.

NICE, however, recommended againstpemetrexed for non small-cell lung cancer.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.